WO2012058269A3 - Methods of treating cancer and other diseases - Google Patents

Methods of treating cancer and other diseases Download PDF

Info

Publication number
WO2012058269A3
WO2012058269A3 PCT/US2011/057820 US2011057820W WO2012058269A3 WO 2012058269 A3 WO2012058269 A3 WO 2012058269A3 US 2011057820 W US2011057820 W US 2011057820W WO 2012058269 A3 WO2012058269 A3 WO 2012058269A3
Authority
WO
WIPO (PCT)
Prior art keywords
cell
reducing
cancer
protein
activity
Prior art date
Application number
PCT/US2011/057820
Other languages
French (fr)
Other versions
WO2012058269A2 (en
Inventor
Andrew S. Goldsborough
Andres Dulcey
Misty Handley
Matthew D. Hall
Kyle Brimacombe
Gary L. Griffiths
Michael M. Gottesman
Original Assignee
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The United States Of America, As Represented By The Secretary, Department Of Health And Human Services filed Critical The United States Of America, As Represented By The Secretary, Department Of Health And Human Services
Publication of WO2012058269A2 publication Critical patent/WO2012058269A2/en
Publication of WO2012058269A3 publication Critical patent/WO2012058269A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C323/60—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton with the carbon atom of at least one of the carboxyl groups bound to nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Disclosed are a method of treating cancer in a cell, a method of enhancing the chemotherapeutic treatment of a cancer treatment agent, a method of reducing resistance of a cancer cell to a chemotherapeutic agent, a method of reducing the amount or activity of an ABC-family mRNA and/or protein, a method of reducing the amount or activity of the ABCB1 mRNA and/or protein or the ABCC1 mRNA and/or protein in an animal cell undergoing cancer treatment, a method of reducing the amount or activity of glutathione and/or Bcl2 in the cancer cell, a method of treating other multidrug resistant diseases, and a method of treating a multidrug resistant cell such as a bacterial multidrug resistant Staphylococcus aureus (MRSA), tuberculosis, fungal infection, or MDR malaria, by administering a compound of the Formula (I): a diastereoisomer thereof, or a pharmaceutically acceptable salt thereof, wherein R1-R4 are as described herein. Also disclosed are pharmaceutical compositions comprising a compound of formula (I), a diastereoisomer thereof, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
PCT/US2011/057820 2010-10-29 2011-10-26 Methods of treating cancer and other diseases WO2012058269A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US40794810P 2010-10-29 2010-10-29
US61/407,948 2010-10-29

Publications (2)

Publication Number Publication Date
WO2012058269A2 WO2012058269A2 (en) 2012-05-03
WO2012058269A3 true WO2012058269A3 (en) 2012-09-27

Family

ID=44971089

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2011/057820 WO2012058269A2 (en) 2010-10-29 2011-10-26 Methods of treating cancer and other diseases

Country Status (1)

Country Link
WO (1) WO2012058269A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUP1600234A2 (en) 2016-04-05 2017-12-28 Mta Termeszettudomanyi Kutatokoezpont Mdr-reversing 8-hydroxy-quinoline derivatives
CN107501390B (en) * 2016-06-14 2021-07-06 首都医科大学 Tiopronin acyl-Met-AA, and synthesis, activity and application thereof
CN111063489B (en) * 2019-12-25 2021-03-16 广饶六合化工有限公司 Preparation method of corrosion-resistant scouring-resistant resistance reducing agent

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3897480A (en) * 1972-10-03 1975-07-29 Santen Pharmaceutical Co Ltd N-(mercaptoacyl)aminoacids
US4299842A (en) * 1978-12-21 1981-11-10 Claudio Cavazza Guaiacol esters of mercaptopropionic acid derivatives, process for preparing same and therapeutical compositions comprising such esters
WO1995033847A1 (en) * 1994-06-07 1995-12-14 Duke University Modulators of multidrug resistance transporters
WO2009067489A1 (en) * 2007-11-20 2009-05-28 Lankenau Institute For Medical Research Disulfide chemotherapeutic agents and methods of use thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US5019369A (en) 1984-10-22 1991-05-28 Vestar, Inc. Method of targeting tumors in humans
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
AU2008213472A1 (en) 2007-02-05 2008-08-14 Aarhus Universitet A method for diagnosing atherosclerotic plaques by measurement of CD36

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3897480A (en) * 1972-10-03 1975-07-29 Santen Pharmaceutical Co Ltd N-(mercaptoacyl)aminoacids
US4299842A (en) * 1978-12-21 1981-11-10 Claudio Cavazza Guaiacol esters of mercaptopropionic acid derivatives, process for preparing same and therapeutical compositions comprising such esters
WO1995033847A1 (en) * 1994-06-07 1995-12-14 Duke University Modulators of multidrug resistance transporters
WO2009067489A1 (en) * 2007-11-20 2009-05-28 Lankenau Institute For Medical Research Disulfide chemotherapeutic agents and methods of use thereof

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
ALAM A: "Enhancement of radiomodulatory effect through liposome encapsulated radio-modifier on cancer bearing mice", BILATERAL SEMINARS OF THE INTERNATIONAL BUREAU, FORSCHUNGSZENTRUM JÜLICH, vol. 30, 1 January 1999 (1999-01-01), pages 83 - 88, XP009160444, ISSN: 0938-7668 *
F M MALAMAS: "Effects of Sulfhydryl Compounds on Cancer Cell Lines: I: N-(2-Mercaptopropionyl)-glycine Exerts Antiproliferating Effects and Antagonizes the Stimulating Effect of Prolactin on MCF-7 Human Breast Cancer Cells", IN VIVO, vol. 21, no. 2, 1 January 2007 (2007-01-01), pages 329 - 332, XP055030483, ISSN: 0258-851X *
FUCHS ET AL: "2-mercaptoproponylglycine and related compounds in treatment of mitochondrial dysfunction and postischemic myocardial damage", ARZNEIMITTEL FORSCHUNG. DRUG RESEARCH, ECV EDITIO CANTOR VERLAG, AULENDORF, DE, vol. 35, no. 9, 1 January 1985 (1985-01-01), pages 1394 - 1402, XP002091095, ISSN: 0004-4172 *
GEORGES A KRAUS AND CO: "A direct introduction of the mercyptoacetic acid unit into amino acid esters", SYNTHESIS, 30 December 2002 (2002-12-30), pages 19 - 20, XP002678346 *
ODA T: "Differential neutralizing effect of tiopronin on the toxicity of neocarzinostatin and SMANCS", JAPANESE JOURNAL OF CANCER RESEARCH, JAPANESE CANCER ASSOCIATION, TOKYO, JP, vol. 80, no. 4, 1 January 1989 (1989-01-01), pages 394 - 399, XP009160452, ISSN: 0910-5050 *
OYA M ET AL: "THIOL COMPOUNDS. I. SYNTHESIS AND ANTIHYPERTENSIVE ACTIVITY OF MERCAPTOACYLAMINO ACIDS", CHEMICAL & PHARMACEUTICAL BULLETIN, PHARMACEUTICAL SOCIETY OF JAPAN, JP, vol. 29, no. 1, 1 January 1981 (1981-01-01), pages 63 - 70, XP002019775, ISSN: 0009-2363 *

Also Published As

Publication number Publication date
WO2012058269A2 (en) 2012-05-03

Similar Documents

Publication Publication Date Title
TW200744586A (en) Therapeutic compounds
WO2011127333A3 (en) Compounds for treating disease, for administering, and for pharmaceutical compositions
WO2006007384A3 (en) Antibiotics containing borinic acid complexes and methods of use
WO2011058474A8 (en) N1-pyrazolospiroketone acetyl-coa carboxylase inhibitors
WO2009135179A3 (en) The use of solid carrier particles to improve the processability of a pharmaceutical agent
WO2008148074A3 (en) Inhibitors of mtor and methods of treatment using same
WO2008154642A3 (en) Antibacterial agents
WO2013106761A3 (en) Antimicrobial agents
WO2011027249A3 (en) Benzimidazole derivatives
GEP20186880B (en) 2-amino-3, 5, 5-trifluoro-3, 4, 5, 6-tetrahydropyridines as bace1 inhibitors for treatment of alzheimer's disease
MY161001A (en) Tetrahydrocarboline Derivative
EP4335511A3 (en) Small molecule trail gene induction by normal and tumor cells as an anticancer therapy
EA200800501A1 (en) QUINOLINE DERIVATIVES AS ANTIBACTERIAL MEANS
WO2007024843A3 (en) Pyrimidinyl-pyrazole inhibitors of aurora kinases
MX2014008020A (en) Phenyl carbamate compounds for use in preventing or treating epilesy.
WO2012119065A3 (en) Antifungal agents and uses thereof
WO2012054721A8 (en) Amino-pyrrolidine-azetidine diamides as monoacylglycerol lipase inhibitors
WO2010115184A3 (en) Hydroxythienoquinolones and related compounds as anti-infective agents
WO2014102592A3 (en) Oxime/substituted quinoxaline-type piperidine compounds and uses thereof
WO2014179154A3 (en) Novel compounds that are erk inhibitors
JP2014511366A5 (en)
EP2215054B8 (en) Amide derivatives as ion-channel ligands and pharmaceutical compositions and methods of using the same
EP2865668A3 (en) Inhibitors and methods of inhibiting bacterial and viral pathogens
WO2007097888A3 (en) Fluoroquinolone carboxylic acid salt compositions
WO2012058269A3 (en) Methods of treating cancer and other diseases

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11782491

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11782491

Country of ref document: EP

Kind code of ref document: A2